Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans

What Was Tested

Researchers studied Glucagon and Somatostatin in this randomized controlled trial publication.

To study the effects of a specific glucagon receptor antagonist (Bay 27-9955), on plasma glucose concentrations and rates of glucose production in response to hyperglucagonaemia in humans.

Who Took Part

The age groups tagged for this paper are adults, men only.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and crossover study.

Because people in this Glucagon study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the participants nor the staff measuring them knew who was on Glucagon, so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Glucagon could be set against what happens without it.

Each person switched between Glucagon and the comparison at some point, usually with a gap in between.

Basal glucose production was measured after an overnight fast with [6,6-2H].

What Was Measured

PubMed files the paper under topics including Biphenyl Compounds, Blood Glucose, Glucagon, Glycated Hemoglobin, Hormone Antagonists, Insulin and Receptors, Glucagon.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Glucagon and Somatostatin.

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2001 (Diabetologia), a journal based in Germany.

More context: the Glucagon compound page and the Somatostatin compound page, all human trials.